Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure
Technology Selectively Shuts Down Cancer Reproducing Cells
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female mice
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option
Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio
In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wegovy®️...
NEW YORK , Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with...
Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; additional endpoints demonstrated ~34% improvement in oncology toxicity (CTCAE)...
Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets